 Live moderated video webcast with members of management to discuss its ongoing Phase 12 study of core technology in development, Annamycin for the treatment of Acute Myeloid Leukemia, on Wednesday, September 28 th at 11:00 AM ET HOUSTON , Sept. 23, 2022 PRNewswire -- Moleculin Biotech, Inc., Nasdaq: MBRX Moleculin or the Company, a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter V. 